Literature DB >> 9160879

Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice.

J Weissenberger1, J P Steinbach, G Malin, S Spada, T Rülicke, A Aguzzi.   

Abstract

We have generated a transgenic mouse model for astrocytoma by expressing the v-src kinase under control of the glial fibrillary acidic protein (GFAP) gene regulatory elements in astrocytes. Abnormal astrogliosis was observed in all transgenic animals already at 2 weeks postnatally, frequently followed by the development of dysplastic changes. Later, small proliferative foci arose, and overt astrocytoma developed in the brain and spinal cord in 14.4% of mice after a follow up time of 65 weeks. While early lesions were histologically consistent with low-grade astrocytoma, at later stages most tumors were highly mitotic and frankly malignant. Vascular endothelial growth factor (VEGF) was expressed by tumor cells already at early stages, suggesting induction by v-src, and it was most pronounced in pseudopalisading cells surrounding necrotic areas, implying additional upregulation by hypoxia. In larger lesions, mitotic activity and expression of flk-1, the cognate receptor of VEGF were induced in endothelial cells. Therefore, end-stage tumors mimicked the morphological and molecular characteristics of human glioblastoma multiforme. Time course and stochastic nature of the process indicate that v-src did not suffice for malignant transformation, and that astrocytomas were the result of a multistep process necessitating co-operation of additional genetic events.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9160879     DOI: 10.1038/sj.onc.1201168

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  44 in total

Review 1.  Pathway inhibition: emerging molecular targets for treating glioblastoma.

Authors:  Wolfgang Wick; Michael Weller; Markus Weiler; Tracy Batchelor; Alfred W K Yung; Michael Platten
Journal:  Neuro Oncol       Date:  2011-06       Impact factor: 12.300

Review 2.  Grafting mouse brains: from neurocarcinogenesis to neurodegeneration.

Authors:  A Aguzzi
Journal:  EMBO J       Date:  1998-11-02       Impact factor: 11.598

3.  KX2-361: a novel orally bioavailable small molecule dual Src/tubulin inhibitor that provides long term survival in a murine model of glioblastoma.

Authors:  Michael J Ciesielski; Yahao Bu; Stephan A Munich; Paola Teegarden; Michael P Smolinski; James L Clements; Johnson Y N Lau; David G Hangauer; Robert A Fenstermaker
Journal:  J Neurooncol       Date:  2018-09-20       Impact factor: 4.130

4.  Comparative evaluation of preclinical in vivo models for the assessment of replicating retroviral vectors for the treatment of glioblastoma.

Authors:  Juraj Hlavaty; Gerrit Jandl; Melissa Liszt; Helga Petznek; Marielle König-Schuster; Jenny Sedlak; Monika Egerbacher; Jakob Weissenberger; Brian Salmons; Walter H Günzburg; Matthias Renner
Journal:  J Neurooncol       Date:  2010-07-11       Impact factor: 4.130

5.  Mouse astrocytoma models: embryonic stem cell mediated transgenesis.

Authors:  H Ding; A Guha
Journal:  J Neurooncol       Date:  2001-07       Impact factor: 4.130

Review 6.  Biological mechanisms of glioma invasion and potential therapeutic targets.

Authors:  B B Tysnes; R Mahesparan
Journal:  J Neurooncol       Date:  2001-06       Impact factor: 4.130

Review 7.  Angiogenesis in transgenic models of multistep carcinogenesis.

Authors:  M G D' Angelo; T Afanasieva; A Aguzzi
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

Review 8.  Role of STAT3 in Genesis and Progression of Human Malignant Gliomas.

Authors:  Zangbéwendé Guy Ouédraogo; Julian Biau; Jean-Louis Kemeny; Laurent Morel; Pierre Verrelle; Emmanuel Chautard
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

Review 9.  Vertebrate animal models of glioma: understanding the mechanisms and developing new therapies.

Authors:  Leon Chen; Yuqing Zhang; Jingxuan Yang; John P Hagan; Min Li
Journal:  Biochim Biophys Acta       Date:  2013-04-22

Review 10.  Targeting astrocytomas and invading immune cells with cannabinoids: a promising therapeutic avenue.

Authors:  Eiron Cudaback; Nephi Stella
Journal:  Mol Neurobiol       Date:  2007-07-03       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.